Taysha Gene Therapies

Today, we reported our second quarter 2024 earnings and provided a corporate update. We are pleased with the continued progress we have made across our lead TSHA-102 #genetherapy program in clinical evaluation for #Rettsyndrome. Read the release to learn more: https://lnkd.in/gE4kqsBD

Next week, we will announce our second quarter 2024 earnings and provide a corporate update. For more information, visit: https://lnkd.in/gcJ6MiCs

Last week, members of the Taysha team attended the International Rett Syndrome Foundation’s ASCEND 2024 Rett Syndrome National Summit! After connecting with families, community advocates, and the leading clinicians and scientists in #Rettsyndrome, we left #IRSF2024 feeling inspired by the research and advancements in the Rett space. We are grateful for IRSF’s continued support as we work together with the Rett community to investigate a potential #genetherapy for Rett syndrome.

Today, we announced positive longer-term clinical data from the low dose cohort of our ongoing REVEAL Phase 1/2 adolescent and adult trial as well as initial clinical data from our REVEAL Phase 1/2 pediatric trial evaluating TSHA-102 in #Rettsyndrome. Tune in to our webcast today at 8:00 a.m. ET to discuss the clinical data. Read the press release and register for the webcast: https://lnkd.in/egEVTtVG

We will be hosting a live webcast on June 18 to discuss new clinical data from the REVEAL Phase 1/2 adolescent and adult trial and the REVEAL Phase 1/2 pediatric trial evaluating TSHA-102 in #Rettsyndrome. The data will also be presented at the 2024 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting from June 18-19. Register for the webcast and learn more: https://lnkd.in/eVqnnir7

Today we celebrate Clinical Trials Day, a day to recognize and reflect on the learnings, progress and medical developments that have resulted from clinical trials around the world. We’d like to thank the individuals and families who participate in clinical trials, as well as those who lead and analyze the clinical research. Your efforts and involvement have drastically improved the lives of many and have helped pave the way for the future development of new medicines. #CTD2024 #ClinicalTrialsDay #ClinicaTrials 

Today, we announced our first quarter 2024 earnings and provided an update on our TSHA-102 #genetherapy program in clinical evaluation for #Rettsyndrome. Read the release to learn more about the recent progress we have made to advance TSHA-102: https://lnkd.in/e3dwYMpS

We’re thrilled to share the recent promotion of Meredith Schultz, MD, MS to Chief Medical Officer and Rumana Haque-Ahmed to Chief Regulatory Officer. Dr. Schultz and Ms. Haque-Ahmed have been instrumental in the development of our TSHA-102 program in clinical evaluation for #Rettsyndrome, and we look forward to their continued leadership as we work toward our mission. Congratulations on your well-deserved new roles! Learn more about our team here: https://lnkd.in/eKtHiGYS

Next week, we will announce our first quarter 2024 earnings and provide a corporate update. For more information, visit: https://lnkd.in/e9yzk9kC

We’re pleased to share that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for TSHA-102 in Rett syndrome. This important milestone supports us on our mission to bring a potentially transformative #genetherapy to all patients and families living with #Rettsyndrome. Learn more: https://lnkd.in/gwvX3Dj3 #RMAT #RMATDesignation